Clinical Trial Update: Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating DE-105 ophthalmic solution for persistent corneal epithelial defect has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Persistent Corneal Epithelial Defect

Drugs mentioned

• DE-105 Ophthalmic Solution (DE-105)

Snippet

Sponsor: Santen Pharmaceutical Co., Ltd. | Conditions: Persistent Corneal Epithelial Defect | Phase 2 | Status: COMPLETED